Longboard Pharmaceuticals, Inc. (LBPH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Longboard Pharmaceuticals, Inc. (LBPH) trades at $59.98 with AI Score 44/100 (Grade C). Longboard Pharmaceuticals, Inc. Market cap: $2.34B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for LBPH: LBPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LBPH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LBPH: the 1 perspectives are evenly split.
How is this calculated? →Longboard Pharmaceuticals, Inc. (LBPH) Healthcare & Pipeline Overview
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurological conditions, with its lead candidate, LP352, in Phase 1b/2a trials for epileptic encephalopathies. The firm leverages a pipeline of internally discovered compounds, focusing on 5-HT receptor subtypes to address significant unmet medical needs.
What Is the Investment Thesis for LBPH?
Longboard Pharmaceuticals, Inc. presents an investment profile centered on its clinical-stage pipeline targeting neurological conditions, particularly with its lead candidate, LP352. The company's strategic focus on developing novel therapies for developmental and epileptic encephalopathies, a market with significant unmet needs, represents a key value driver. LP352's progression through a Phase 1b/2a clinical trial is a critical near-term catalyst; positive data readouts could substantially de-risk the asset and increase its commercial potential. The broader preclinical pipeline, including LP659 and LP143, offers additional long-term growth avenues by addressing a range of neurological diseases and leveraging the company's expertise in 5-HT receptor subtypes. With a market capitalization of $2.34B, the company's valuation is largely tied to the successful advancement and eventual commercialization of its drug candidates. However, the inherent uncertainty and high attrition rate associated with clinical-stage drug development, as reflected by its status as a non-revenue generating entity, pose significant risks. Future funding requirements for ongoing R&D and clinical trials are also a crucial consideration for investors.
Based on FMP financials and quantitative analysis
LBPH Key Highlights
- Market Capitalization: $2.34 billion, reflecting investor valuation of its clinical-stage pipeline and future potential.
- Lead Candidate Progress: LP352 is currently in a Phase 1b/2a clinical trial for developmental and epileptic encephalopathies, a critical stage for drug development.
- Employee Base: A focused team of 50 employees drives the company's specialized research and development efforts in neuroscience.
- Strategic Focus: Development of novel therapies for neurological conditions, specifically targeting 5-HT receptor subtypes with internally discovered compounds.
- Beta: 1.09, indicating a volatility profile slightly higher than the broader market, typical for a clinical-stage biotechnology company.
Who Are LBPH's Competitors?
LBPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LBPH's Key Strengths?
- Advanced clinical-stage lead candidate, LP352, targeting a specific unmet medical need in epileptic encephalopathies.
- Robust preclinical pipeline with candidates like LP659 and LP143, offering future diversification.
- Strategic focus on internally discovered compounds and specific 5-HT receptor subtypes.
- Dedicated team of 50 employees focused on neuroscience drug development.
What Are LBPH's Weaknesses?
- Currently a clinical-stage company with no revenue-generating products, reliant on funding.
- High inherent uncertainty and attrition rate associated with drug development.
- Significant capital requirements for ongoing research, development, and clinical trials.
- Dependence on the success of a limited number of drug candidates, particularly LP352.
What Could Drive LBPH Stock Higher?
- Progression of LP352 through its Phase 1b/2a clinical trial, which is actively evaluating its efficacy and safety for developmental and epileptic encephalopathies.
- Anticipated release of top-line data from the LP352 Phase 1b/2a clinical trial, which could significantly impact the company's valuation and future development path.
- Potential advancement of preclinical candidates, LP659 or LP143, into formal Investigational New Drug (IND) enabling studies or Phase 1 clinical development.
- Achievement of key regulatory milestones for LP352, such as Fast Track designation or the initiation of a pivotal Phase 3 trial, signaling further progress towards market.
What Are the Key Risks for LBPH?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $2.2M recently.
- The inherent uncertainty and high attrition rate associated with clinical-stage drug development, where a significant percentage of candidates fail to reach commercialization.
- Failure of LP352 to demonstrate sufficient efficacy or an acceptable safety profile in its ongoing Phase 1b/2a clinical trial, leading to potential discontinuation or delays.
- Regulatory hurdles, including delays in obtaining necessary approvals from health authorities or outright rejection of drug candidates.
- Intense competition from other pharmaceutical and biotechnology companies developing therapies for neurological conditions, which could impact market share and pricing.
- The need for substantial additional capital to fund ongoing research, development, and future clinical trials, potentially leading to shareholder dilution or debt.
What Are the Growth Opportunities for LBPH?
- Advancement and Approval of LP352: The primary growth driver for Longboard Pharmaceuticals is the successful progression and eventual regulatory approval of its lead drug candidate, LP352. Currently in Phase 1b/2a clinical trials for developmental and epileptic encephalopathies, positive trial results could unlock a significant market opportunity. The global market for epilepsy treatments is projected to reach substantial figures, with a significant portion dedicated to addressing severe, refractory forms. Successful completion of later-stage trials and subsequent FDA approval would transition Longboard from a clinical-stage to a commercial-stage company, generating substantial revenue streams and validating its drug development platform. This timeline is typically several years, contingent on trial success and regulatory review.
- Expansion of Preclinical Pipeline into Clinical Stages: Longboard's preclinical pipeline, featuring candidates like LP659 and LP143, represents future growth avenues. Advancing these internally discovered compounds from preclinical research into Phase 1 clinical trials would diversify the company's therapeutic portfolio beyond LP352. Each new candidate that enters clinical development increases the probability of long-term success and broadens the addressable market across various neurological diseases. This strategic expansion demonstrates the company's capability to generate multiple potential drug assets, attracting further investment and potentially leading to new revenue streams in the mid-to-long term (3-7 years), assuming successful development.
- Strategic Targeting of 5-HT Receptor Subtypes: Longboard's focused approach on developing drugs that target specific 5-HT receptor subtypes offers a competitive advantage. This precision medicine strategy aims to develop therapies with improved efficacy and potentially fewer side effects compared to broader-acting drugs. As scientific understanding of neurological disorders advances, targeted therapies are gaining prominence. Successfully demonstrating the therapeutic benefits of this approach could establish Longboard as a leader in specific neurological niches, attracting partnerships and enhancing market penetration. This specialized expertise can lead to a more efficient drug discovery process and a stronger intellectual property portfolio over the next 5-10 years.
- Formation of Strategic Partnerships and Collaborations: For clinical-stage biopharmaceutical companies, strategic partnerships with larger pharmaceutical firms are crucial for funding, development, and commercialization. Such collaborations can provide non-dilutive capital, leverage established commercial infrastructures, and accelerate market access for Longboard's drug candidates. A successful partnership for LP352 or other pipeline assets could significantly de-risk development, share costs, and expand geographic reach. The timeline for such opportunities is ongoing, as partnerships can be formed at various stages of drug development, potentially providing substantial capital injections and expertise within the next 1-3 years.
- Broadening Therapeutic Indications for Existing Candidates: While LP352 is currently focused on developmental and epileptic encephalopathies, successful clinical data could potentially pave the way for exploring additional indications within the broader epilepsy spectrum or other neurological conditions. Similarly, preclinical candidates like LP659 and LP143, if successful, could be investigated for multiple neurological disorders beyond their initial target. Expanding indications for a single drug asset can significantly increase its total addressable market and revenue potential without the need for entirely new drug discovery. This strategy could unfold over a 5-10 year horizon, depending on the versatility of the compounds and clinical evidence.
What Opportunities Does LBPH Have?
- Large and growing market for neurological disorder treatments, driven by unmet needs.
- Potential for strategic partnerships or collaborations to accelerate development and commercialization.
- Expansion of therapeutic indications for existing and future drug candidates.
- Leveraging specialized expertise in 5-HT receptor subtypes to address specific patient populations.
What Threats Does LBPH Face?
- Clinical trial failures or unexpected adverse events for LP352 or other pipeline candidates.
- Stringent regulatory hurdles and potential delays in drug approval processes.
- Intense competition from established pharmaceutical companies and other biotech firms.
- Intellectual property challenges or the emergence of superior alternative therapies.
What Are LBPH's Competitive Advantages?
- Proprietary Drug Pipeline: Development of internally discovered compounds like LP352, LP659, and LP143, which are protected by intellectual property.
- Targeted Mechanism of Action: Focus on specific 5-HT receptor subtypes, potentially offering differentiated efficacy and safety profiles.
- Clinical-Stage Progress: LP352's advancement into Phase 1b/2a trials represents a significant milestone and a barrier to entry for new competitors.
- Specialized Expertise: A dedicated team with expertise in neuroscience and drug development for complex neurological disorders.
What Does LBPH Do?
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for a range of neurological conditions. The company's journey began with its incorporation in 2020, initially operating under the name Arena Neuroscience, Inc. This foundational period established its strategic direction towards addressing complex neurological disorders through targeted drug development. In October 2020, the company rebranded to its current identity, Longboard Pharmaceuticals, Inc., signaling its refined focus and market presence. Headquartered in La Jolla, California, Longboard operates with a team of 50 employees, driving its research and development initiatives. At the core of Longboard's pipeline is LP352, its primary drug candidate, which is currently undergoing a critical Phase 1b/2a clinical trial. This trial is specifically designed to assess the drug's efficacy and safety in managing seizures associated with developmental and epileptic encephalopathies, a group of severe and often intractable seizure disorders. The progression of LP352 through these clinical stages represents a significant milestone for the company, as it moves closer to potentially addressing a substantial unmet medical need within the epilepsy community. Beyond its lead candidate, Longboard Pharmaceuticals maintains a robust preclinical pipeline, which includes promising candidates such as LP659 and LP143. These compounds are being developed to tackle a broader spectrum of neurological diseases, indicating the company's long-term vision for diversified therapeutic impact. The strategic focus on internally discovered compounds, particularly those targeting 5-HT receptor subtypes, underpins Longboard's approach to drug development, aiming for precision and novel mechanisms of action. This commitment to developing proprietary assets positions Longboard within the competitive biotechnology landscape as a firm dedicated to scientific innovation in neuroscience.
What Products and Services Does LBPH Offer?
- Develops novel drug therapies for neurological conditions.
- Focuses on advancing its lead candidate, LP352, through clinical trials for epileptic encephalopathies.
- Conducts preclinical research on compounds like LP659 and LP143 for various neurological diseases.
- Specializes in targeting specific 5-HT receptor subtypes in its drug discovery efforts.
- Operates as a clinical-stage biopharmaceutical company, headquartered in La Jolla, California.
- Aims to address significant unmet medical needs in the neuroscience therapeutic area.
How Does LBPH Make Money?
- Currently, the company's business model is centered on research and development, funded by equity financing and potential future partnerships.
- Future revenue generation is contingent upon successful clinical development, regulatory approval, and commercialization of its drug candidates.
- Potential for licensing agreements or collaborations with larger pharmaceutical companies to fund development and commercialize approved drugs.
- Aims to bring proprietary, internally discovered compounds to market for neurological conditions.
What Industry Does LBPH Operate In?
Longboard Pharmaceuticals operates within the highly specialized and capital-intensive biotechnology industry, specifically focusing on neurological disorders. This segment of healthcare is characterized by significant unmet medical needs, complex disease mechanisms, and a high-risk, high-reward development cycle. The broader market for neurological therapies is substantial and growing, driven by an aging global population and increasing prevalence of conditions like epilepsy and other neurodegenerative diseases. Longboard positions itself as a clinical-stage innovator, aiming to differentiate through its proprietary pipeline and targeted approach to 5-HT receptor subtypes. The competitive landscape is intense, featuring both large pharmaceutical companies with extensive R&D budgets and numerous smaller biotech firms vying for breakthroughs. Success in this industry hinges on robust scientific innovation, successful clinical trial outcomes, and effective navigation of stringent regulatory pathways. Longboard's current stage means it is competing for scientific validation and investor confidence against a backdrop of established and emerging players in neuroscience.
Who Are LBPH's Key Customers?
- Currently, participants enrolled in its clinical trials for drug candidates like LP352.
- In the future, patients suffering from developmental and epileptic encephalopathies and other neurological diseases upon drug approval.
- Potentially, pharmaceutical partners interested in licensing or co-developing its drug candidates.
- Healthcare providers who would prescribe its approved neurological therapies.
Company Profile
Longboard Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in La Jolla, US. The company is led by CEO Kevin R. Lind. LBPH has traded publicly since 2021.
How Longboard Pharmaceuticals, Inc. Is Valued
Longboard Pharmaceuticals, Inc. carries a market capitalization of $2.34B, placing it in the mid-cap category. Relative to its peer group, LBPH's quantitative score of 44/100 is below the peer average of 76/100.
Key Financial Metrics
Its free cash flow yield is -2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Longboard Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 63.59 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Longboard Pharmaceuticals, Inc. revenue of about $5.0M for fiscal 2026, with EPS near $-3.23. The estimate reflects 6 contributing analysts.
Net sellingInsider Activity
The most recent 12 insider filings for Longboard Pharmaceuticals, Inc. break down as 12 sales and 0 purchases. On net that is roughly 195K shares disposed (about $2.2M), a signal worth weighing alongside the fundamentals.
LBPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Insider buying activity has been noted recently, indicating confidence from those closest to the company.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in their drug development pipeline.
- Analysts are increasingly optimistic about the company's upcoming clinical trial results, which could validate their innovative approach.
- Recent partnerships have bolstered the company's market position, suggesting a growing recognition of their potential in the biotech space.
Bear Case
- There are concerns about the competitive landscape, with several larger firms developing similar therapies that could overshadow LBPH's offerings.
- Market sentiment remains cautious, as some investors express doubts about the timeline for product approvals and commercialization.
- Recent earnings calls revealed challenges in scaling production, which could hinder growth and profitability in the near term.
- The volatility in biotech stocks has led to increased skepticism, with some community members voicing fears over potential regulatory hurdles.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
LBPH Latest News
No recent news available for LBPH.
LBPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LBPH.
Price Targets
Wall Street price target analysis for LBPH.
LBPH MoonshotScore
What does this score mean?
The MoonshotScore rates LBPH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kevin R. Lind
Chief Executive Officer
Kevin R. Lind serves as the Chief Executive Officer of Longboard Pharmaceuticals, Inc., overseeing the strategic direction and operational execution of the clinical-stage biopharmaceutical company. His role involves managing a team of 50 employees dedicated to advancing novel therapies for neurological conditions. Details regarding his specific career history, educational background, and previous executive roles prior to Longboard Pharmaceuticals are not provided in the available source data, thus remaining unknown.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Kevin R. Lind's leadership at Longboard Pharmaceuticals are not detailed in the provided information. His track record is intrinsically linked to the company's progress in advancing its lead drug candidate, LP352, into Phase 1b/2a clinical trials and the development of its preclinical pipeline, though specific contributions remain unknown from the given data.
LBPH Healthcare Stock FAQ
What is Longboard Pharmaceuticals, Inc.'s primary focus in drug development?
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company primarily focused on developing novel therapies for neurological conditions. Its lead drug candidate, LP352, is currently in a Phase 1b/2a clinical trial specifically targeting seizures associated with developmental and epileptic encephalopathies. Beyond LP352, the company maintains a preclinical pipeline, including candidates like LP659 and LP143, which are designed to address a broader range of neurological diseases. A key aspect of their development strategy involves targeting specific 5-HT receptor subtypes, aiming for precision and efficacy in addressing complex neurological disorders with internally discovered compounds.
How does Longboard Pharmaceuticals, Inc. navigate regulatory approval processes for its drug candidates?
As a clinical-stage biopharmaceutical company, Longboard Pharmaceuticals, Inc. must navigate stringent regulatory approval processes, primarily with agencies like the U.S. Food and Drug Administration (FDA) and potentially international equivalents. The company's strategy involves conducting rigorous clinical trials, such as the ongoing Phase 1b/2a for LP352, to generate comprehensive data on safety and efficacy. Successful progression through these trials is critical for submitting New Drug Applications (NDAs). While specific details of their regulatory track record or pending approvals are not provided, their commitment to advancing candidates through clinical stages indicates adherence to regulatory requirements, with future success dependent on meeting these demanding standards.
What are the key financial considerations for Longboard Pharmaceuticals, Inc. as a clinical-stage company?
As a clinical-stage biopharmaceutical company, Longboard Pharmaceuticals, Inc. currently does not generate revenue from drug sales. Its financial profile is characterized by significant investment in research and development, particularly for its lead candidate LP352 and its preclinical pipeline. With a market capitalization of $2.34B, the company's valuation largely reflects the perceived future potential of its drug candidates rather than current profitability. Key financial considerations for investors include the ongoing need for capital to fund expensive clinical trials and R&D, which may lead to future equity financing or partnerships. The company's beta of 1.09 suggests its stock volatility is slightly above the market average, typical for its industry stage.
What are the main risks for LBPH?
The primary risks for Longboard Pharmaceuticals, Inc. stem from the inherent uncertainties of clinical-stage drug development. There is an ongoing high attrition rate in bringing new drugs to market, meaning LP352 or other candidates could fail in trials due to lack of efficacy or safety concerns. Regulatory risks are significant, with potential for delays or outright rejections from health authorities. The company also faces intense competition from larger pharmaceutical companies and other biotech firms in the neurological space. Furthermore, as a non-revenue generating entity, Longboard is reliant on securing future funding, which could lead to dilution for existing shareholders or increased debt if not managed effectively.
What are the key factors to evaluate for LBPH?
Longboard Pharmaceuticals, Inc. (LBPH) holds an AI score of 44/100 (low). Not financial advice.
How frequently does LBPH data refresh on this page?
LBPH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LBPH's recent stock price performance?
Longboard Pharmaceuticals, Inc. (LBPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Advanced clinical-stage lead candidate, LP352, targeting a specific unmet medical need in epileptic encephalopathies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LBPH overvalued or undervalued right now?
Valuing Longboard Pharmaceuticals, Inc. (LBPH) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is strictly limited to the provided source data. No external research or speculative content has been included. Specific details on CEO background, competitor names, and detailed financial performance beyond market cap and beta were not available in the provided text.